

Slovakia

YOUNG BIOTECHNOLOGY COMPANY OF THE YEAR


Selecta Biotech SE

www.selectabiotech.com | +421 948 176 160 | info@selectabiotech.com


SELECT  **Biotech**

Headquartered in Bratislava, Selecta Biotech SE is a European joint-stock company whose goal is to market a patented technology for the selective recognition of nucleic acids. In its mission to develop quality healthcare products through science-based evidence, Selecta strives to bring safe and reliable treatment modalities that support patients with unmet medical needs, transforming the potential of modern medical science into products and technologies that enhance or even save lives. To address the issue of drug promiscuity leading to numerous side-effects, Selecta developed a new generation of oligonucleotide-based inhibitors with proprietary structural design and pursues milestone-driven projects that are focused on pre-clinical testing and translation of therapeutic leads across various diagnoses. The company's target-market are oligonucleotide therapeutics and drug discovery services that would greatly benefit from the safety of such inhibitors.

The unique structural design of therapeutic oligonucleotides can be applied universally, and Selecta aims to utilise it in a variety of diagnoses. Selecta believes that these innovations can be the key to achieving success in developing therapeutics for a broad range of currently intractable and devastating diseases. Whilst its primary objective is to develop solutions that eliminate drug toxicity in oncological diagnoses, early-stage pre-clinical validation of



**SELECTA STRIVES
TO BRING SAFE AND
RELIABLE TREATMENT
MODALITIES THAT
SUPPORT PATIENTS WITH
UNMET MEDICAL NEEDS.**



inhibitors has already begun for cardiovascular and renal diseases, alongside viral infections. The company has an intense focus on research and development across its Therapeutics and Diagnostics divisions and has six state-of-the-art laboratories in operation.

The judging panel was particularly impressed by the company's leading platform, ESiNAR-X®. It is Selecta Biotech SE's proprietary technology for selective nucleic acid recognition, and it deliberately combines aspects of bioinformatics, nucleic acid chemistry, and thermodynamics to achieve exclusive recognition of one target RNA. ESiNAR-X® has already shown unmatched accuracy in target recognition, confirming the fascinating possibility that off-target-related side effects of therapeutics can be eliminated. For patients that suffer from oncological diseases, the innovative platform can provide a number of benefits, including safer, more compliant treatments, improved sustainability, and a superior quality of life.